A1 – HIV and SIV diversity
Positive Selection and Functional Effects of Amino Acid Substitutions in Tat exon 1 during Primary HIV-1C Infection
Raabya Rossenkhan,
University of Botswana, Harvard School of Public Health & Botswana Harvard AIDS Institute, Botswana & United States
A5 - Entry (attachment, receptors and co-receptors, penetration and tropism)
HIV-1 entry and trans-infection in astrocytes: implications for cure and eradication
Lachlan Gray,
Monash University & Burnet Institute, Australia
Abstract
A8 - Regulation of viral gene expression and replication
Suppression of HIV-1C virus production in human PBMCs by dsRNA induced Chromatin remodeling of LTR promoter
Anand Singh,
All India Institute of Medical Sciences, India
Abstract
A9 - Cellular factors necessary for HIV replication
Restriction of HIV-1 infection in dendritic cells avoids induction of IFN-α-mediated responses and reduces chemokine expression. Impact on viral escape and establishment of CD4 reservoirs
Esther Calonge,
Instituto de Salud Carlos III, Spain
Abstract
Involvement of Human Topoisomerase II isoforms in the Strand transfer events of HIV-1 Reverse Transcription
Sunnam Lokeswara Balakrishna,
University of Hyderabad, India
Abstract | Poster
A10 - Cellular and tissue reservoirs
Efficient infection of healthy donors´ monocyte derived macrophages by erythrocyte-associated HIV
Lucia Fazzi,
Buenos Aires University, Argentina
Abstract
Erythrocyte-associated HIV in a model of HIV infection
Lucia Fazzi,
Buenos Aires University, Argentina
Abstract
Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments
Slim Fourati,
Inserm, France
Abstract | Poster
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy
Slim Fourati,
Inserm, France
Abstract | Poster
T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection
Laurence Weiss,
Institut Pasteur & Université Paris Descartes, France
Abstract | Poster
A11 - Mechanisms of HIV persistence
HIV-1 resistance mutations by ultradeep pyrosequencing in proviral DNA of patients at success of a first line ART
Herve Fleury,
University Hospital of Bordeaux, France
Evaluation of residual HIV-1 replication among individuals receiving different antiretroviral treatment regimens
Ricardo Sobhie Diaz,
Federal University of Sao Paulo, Brazil
Abstract | Poster
A13 - Strategies to target and eradicate reservoirs
Archived HIV-1 CTL Epitopes and HLA I Alleles of Patients at Success of a First Line ART: Toward a New Concept of Curative Vaccine
Herve Fleury,
University Hospital of Bordeaux, France
Establishment of Macaque CD4+ T Cells and CD34+ Hematopoietic Stem Cells resistant to SIV Infection using Zinc Finger Nucleases Technology
Marie-Claire.E. Gauduin,
Texas Biomedical Research Institute, United States
Abstract
Dual approach to HIV-1 cure: Activation of latency and restoration of exhausted virus-specific T cell function
Carey Hwang,
Bristol-Myers Squibb, United States
Abstract
Combination of proteasome and Hsp90 inhibitors induces autophagic cell death in HIV-1-infected macrophages and CD4+ T cells: approaches to elimination of the virus reservoirs
Alexander Kabakov,
Medical Radiology Research Center, Russian Federation
Abstract
Maraviroc (MVC) intensification can activate NFkB through CCR5 and the expression of its target genes in resting CD4+-T-cells in suppressed HIV-1-infected patients (Late Breaker)
Santiago Moreno,
Hospital Ramón y Cajal, Spain
Abstract
Metal Nanoparticles Reduce Intracellular HIV-1 Replication and Stimulate Growth of HIV-1 Infected PBMC
Sellappa K. Prakash,
Naval AIDS Research Center, India
Abstract | Poster
HIV Resistance to Dolutegravir (DTG) Simultaneously Diminishes Viral DNA Integration into Host Cells and Viral Replication Fitness: Implications for HIV Reservoirs
Mark Wainberg,
McGill University, Canada
Abstract
A14 - Mucosal transmission
The intestinal microenvironment affects the susceptibility of DCs to HIV-1
Mariangela Cavarelli,
San Raffaele Scientific Institute, Italy
Abstract
A18 - Innate sensors of HIV
Female genital epithelial cells from HIV-exposed seronegative commercial sex workers express a discrete cytokine/chemokines profile upon toll-like receptor activation
Nyla Dil,
University of Manitoba & Public Health Agency of Canada, Canada
Abstract | Poster
A19 - Intrinsic cellular defences and restriction factors
A Population-based Matched-cohort Study on Insertion/Deletion Polymorphism of the APOBEC3B gene and Risk of HIV-1
Mayumi Imahashi,
Nagoya Medical Center & Nagoya University Graduate School of Medicine, Japan
Abstract | Poster
Increased levels of APOBEC3 and interferon mRNA in PBMC of Highly Exposed Seronegatives Individuals (HESN)
Joel Armando Vázquez Perez,
Instituto Nacional de Enfermedades Respiratorias, Mexico
Abstract
A20 - IFN-I (viral inhibition, immunomodulatory functions)
Characterization of HIV-1 Gag and Nef T cell Responses in an HIV-1 infected Kenyan Population
Robert Langat,
University of Nairobi, Kenya
Abstract
A21- NK cells and dendritic cells
Analysis of NK cell receptor-ligand expression in the prevention of AIDS-defining opportunistic infections in patients with low CD4+ T cell count
Francesco Marras,
Giannina Gaslini Institute, Italy
Abstract | Poster
DC infected by the ANRS MVAHIV vaccine candidate primes NK cells with anti-HIV specific activity through a mechanism involving NKG2D and NKp46 on NK cells, and membrane-bound IL-15 on DC
Uriel Y. Moreno Nieves,
Institut Pasteur, France
Abstract | Poster
A22 - Monocytes and macrophages
HIV-1 stimulates Human Monocytes to produce BAFF through Type I IFN and its secretion level shows sex-related differences
Alejandro Martin Gomez,
Université Laval, Canada
Abstract | Poster
HIV-1 virion accumulation and ATP-Induced release in human primary monocyte-derived macrophages
Francesca Graziano,
San Raffaele Scientific Institute & San Raffaele University, Italy
Abstract | Poster
A24 - Antibody diversity and function
Generation and characterization of neutralizing anti-V3 scFvs against HIV-1 clade C
Rajesh Kumar,
All India Insitute of Medical Sciences, India
Abstract
Antibody and T cell response to the protease cleavage sites drive extensive mutations and correlated with protection against higher dose of SIVmac239 challenge and disease progression in Cynomolgus macaques
Ma Luo,
National Microbiology Laboratory & University of Manitoba, Canada
Abstract
A27 - Cellular immunity
Assessing the Role of Antigen-Specific CD8+ T cells in Delayed Progression to AIDS
Melissa Herman,
University of Manitoba, Canada
Abstract
HIV-1 Env-specific conformational ADCC epitopes: potential utility for HIV vaccine design
Vijaya Madhavi,
University of Melbourne, Australia
Abstract
HIV-1 infection reduces emigration of mature thymocytes from the human thymus by downregulation of the sphingosine-1-kinase receptor S1PR1
Rachel S. Resop,
AIDS Institute at UCLA, United States
Abstract
A28 - Mucosal immunity
Severe depletion and exhaustion of mucosal-associated invariant T (MAIT) cells in HIV-1 infected patients
Jan van Lunzen,
University Medical Center Hamburg-Eppendorf, Germany
Abstract
A29 - Viral determinants of pathogenesis
NEF-mediated down-regulation of MHC I expression in thymocytes may affect the pathogenicity of a pediatric isolate of X4 HIV-1
Robert Furler,
UCLA AIDS Institute & Edison State College, United States
Abstract | Poster
A30 - Acute and early HIV/SIV infection
Analysis of HLA-restricted HIV-specific CD8 T cell responses and viral adaptation in patients with acute HIV infection prior to full seroconversion
Niamh Keane,
Murdoch University, Australia
Abstract
A41 - Elite controllers
An elite controller in pregnancy - towards a definition of recovery, though not cure?
Sophia Archuleta,
National University of Singapore, Singapore
Abstract | Poster
HIV-1 Vif- and Nef-responses in controllers present higher magnitude and target more conserved, less promiscuous epitopes than responses seen in typical progressors
Leandro Tarosso,
University of Sao Paulo, Brazil
Abstract
A44 - Highly exposed seronegative individuals (HESN)
Polymorphisms in the IRF1 gene assoc iated with reduced HIV susceptibility and their impact on plasma and cervical lavage cytokine/chemokine expression
Aida Sivro,
University of Manitoba, Canada
Abstract
A45 - Correlates of protection
Functional cure after long term HAART initiated during early HIV infection - a comprehensive case study
Jan van Lunzen,
University Medical Center Hamburg-Eppendorf, Germany
Abstract | Poster
A46 - HIV drug development
Evaluation of a panel of selective inhibitors of PKCθ or Lck for controlling HIV-1 replication in CD4+ T cells
Maria Teresa Coiras,
Insituto de Salud Carlos III, Spain
Abstract
Safety and Efficacy study of a herbal concoction used for alternative/complementary treatment of HIV infection in Nigeria
Ojezele Matthew Obaineh,
Lead City University & Igbinedion University, Nigeria
Abstract | Poster
A47 - Mechanisms of anti-retroviral drug resistance
The real cause of increasing HIV opportunistic infections in CHUK (Kigali University Teaching Hospital)
Dominique Savio Habimana,
Rwanda Medical Association, Rwanda
Abstract
Secondary resistance mutations in the R263K integrase inhibitor resistance pathway
Thibault Mesplède,
McGill Universtiy AIDS Centre, Canada
Abstract
A49 - Nucleic acid based HIV and SIV therapy development
Characterization of a new use for acyclovir and tenofovir using human cervico-vaginal tissue ex vivo
Christophe Vanpouille,
NIH/NIHCD, United States
Abstract
A50 - Design of approaches targeting inflammation/immune activation
Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals
Jan van Lunzen,
University Medical Center Hamburg-Eppendorf, Germany
Abstract | Poster
A51 - HIV-hepatitis virus interactions
Hepatitis B virus coinfections: Prevalence and CD4 profile among patients on comprehensive care services in Kenya
Joseph Mwangi,
Kenya Medical Research Institute & Jomo Kenyatta University, Kenya
Abstract
A52 - Tuberculosis and other mycobacteria
Anti-mycobacterial activity is enhanced by blocking the Tim3-Galectin 9 interaction in HIV patients
Maria Isabel Sada-Ovalle,
Insituto Nacional de Enfermedades Respiratorias, Mexico
Abstract
B56 - Therapeutic vaccine and immune based therapy trials
cART reduces antibody-dependent cellular cytotoxicity to HIV: Implications for Therapeutic Vaccines (Late Breaker)
Vijaya Madhavi,
University of Melbourne, Australia
Abstract
B58 - 5-drug HAART during Primary HIV Infection Leads to a Reduction of Proviral DNA Levels in Comparison to Levels Achievable during Chronic Infection
5-drug HAART during Primary HIV Infection Leads to a Reduction of Proviral DNA Levels in Comparison to Levels Achievable during Chronic Infection
Eva Wolf,
MUC Research, Germany
Abstract | Poster
D24 - Impact of financial crises on the HIV funding and response
Building the Path to the End of AIDS: How investments in HIV prevention research and development responded to the global economic downturn, new research results and funding trends 2000-2012
Mitchell Warren,
AVAC, United States
Abstract